Weight Loss Aids Conception in Infertile Obese Women
(MedPage Today) -- Benefit seen irrespective of age, baseline BMI, cycle regularity
CONCLUSION: Validated data are of vital importance for health managers to monitor users. The population of this study is predominantly elderly, obese, requiring multi-professional care to slow the progression of the disease and decrease morbidity and mortality. PMID: 29927457 [PubMed - as supplied by publisher]
Conclusion: The prevalence of breakfast skipping was low, and this is consistent with the findings of other studies in the literature. Mental health was significantly associated with breakfast consumption. In order to increase the rate of breakfast consumption, interventions should be developed for specific target groups. PMID: 29927569 [PubMed - in process]
Conclusion: Several health service indicators need to be improved including: low OP visit, low birth weight, high underweight and overweight among children under aged five, low coverage of urine micro albumin, DR screening, and feet examination among DM patients, low coverage of urine protein among HT patients, and high percentage of uncontrolled DM and HT patients. PMID: 29926717 [PubMed - in process]
Conclusion: Previously diagnosed GDM women have higher prevalence of metabolic syndrome after delivery. Obesity before pregnant is a strong independent risk factor for this condition. PMID: 29926712 [PubMed - in process]
This study aims to verify the morphokinetic criteria to discriminate good morphological blastocyst (group I) from poor morphological blastocyst (group II) by using Primo vision® (Vitrolife, Sweden). Material and Method: The prospective study was performed in infertile couples treated with assisted reproductive technology at Thammasat Fertility Center, Thailand, in 2015. The morphokinetic study was compared between the two groups by t-test and Mann-Whitney U test with p
Authors: Yancheva N, Strashimirov D, Hrischev V, Tchervenyakova T, Nikolova M, Aleksiev I Abstract HIV-associated lymphoma was first classified as an AIDS-defining disease by the American Center for Disease Control and Prevention (CDC) in 1985. Non-Hodgkin's lymphomas (NHLs) are frequent malignancies in AIDS patients. The risk of NHL in the case of an underlying HIV infection is estimated to be 100 times greater than in the general population, and it increases with the progression of the retrovirus-related immunosuppression. Cases of HIV-related non-Hodgkin's lymphoma are widely documented in the literature. In thi...
Authors: Costantini A, Tontini C, Rocchi M, Martini M, Butini L Abstract Reduced dose schedules may be feasible options to simplify antiretroviral therapy (ART) in selected HIV-1-infected individuals. Efficacy and safety of a Day-on, Day-off (DODO) schedule of tenofovir disoproxil fumarate, emtricitabine and efavirenz (FTC/TDF/EFV) single tablet regimen (STR) was assessed. Twenty-seven patients were prescribed the DODO schedule and were monitored for 48 weeks. Switching criteria were: no previous ART failure, no AIDS-defining illnesses, T CD4 cell nadir>200/mmc, and HIV-RNA below detection limit (40 copies/mL) f...
New rules aiming to tackle child obesity have been broadly welcomed - with some reservations.
Conclusion: Our results corroborate the protective effect of HIV positivity vis-à -vis gliomas. This "antiglioma effect" could be attributed to either the HIV, its treatment, or both. Future studies focused on this "effect" may help unveil better preventative and possible therapeutic avenues for gliomas. PMID: 29930869 [PubMed]
Conclusion: We think that exposures to hazardous substances migrating from FCAs require more attention. We recommend a) limiting the number and types of chemicals authorized for manufacture and b) developing novel approaches for assessing the safety of chemicals in FCAs, including unidentified chemicals that form during or after production. https://doi.org/10.1289/EHP644 Received: 10 June 2016 Revised: 08 June 2017 Accepted: 09 June 2017 Published: 11 September 2017 Address correspondence to J. Muncke, Food Packaging Forum, Staffelstrasse 8, 8045 Zurich, Switzerland. Telephone: 41-44-5155255. Email: jane.muncke@fp-fo...